AbbVie faced no shortage of criticism and questioning over its decision to abandon its proposed $55 billion Shire buyout back in 2014. But after years of legal back-and-forth, the company has escaped one high-profile case from hedge funds that alleged the company misled them about its true intentions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,